The biopharmaceutical industry witnessed a resurgence in the third quarter of 2024, driven by investor confidence and a wave of new FDA approvals. Key players like Bristol-Myers Squibb, Gilead Sciences, and Sanofi saw significant market capitalization gains, highlighting the industry’s potential for continued growth despite earlier challenges.